openPR Logo
Press release

Global Myelodysplastic Syndrome (MDS) Treatment Share 2021 Growth Challenges, Opportunities and Future Trends 2027

01-20-2022 12:49 PM CET | Health & Medicine

Press release from: Orion Market Research

The global myelodysplastic syndrome (MDS) treatment market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are driving the market growth include a rise in public awareness about myelodysplastic syndromes and their early diagnosis and the availability of new treatment options for MDS. Moreover, early diagnosis of MDS is important, as it significantly increases the quality of life in patients, reducing the chances of recurrent blood transfusion. Increasing regulatory approvals is another factor that is anticipated to fuel the market during the forecast period. For instance, in November 2018, Lupin obtained the US FDA approval of its Decitabine for Injection, 50 mg/vial, single-dose vial, a generic version of Otsuka Pharmaceutical Co. Ltd.'s Dacogen for Injection, 50 mg/vial, single-dose vial. Lupin’s generic version is indicated for the treatment of patients with myelodysplastic syndromes (MDS), which incorporates previously treated and untreated, de novo, as well as secondary MDS of all French-American-British subtypes.

To Request a Sample of our Report on Global Myelodysplastic Syndrome (MDS) Treatment Market: https://www.omrglobal.com/request-sample/myelodysplastic-syndrome-mds-treatment-market

Several Drug manufacturing companies and government organizations are focusing more on spreading awareness about the disease by providing funding and conducting awareness programs. For instance, in October 2018, Grupo Biotoscana, a Latin American biopharmaceutical company conducted a campaign for Myelodysplastic Syndrome World Awareness Day, which is celebrated on 25th October. GBT Grupo Biotoscana launched a campaign to raise awareness and educate about the disease throughout the month. Moreover, increasing launch and approval of Azacitidine in some regions is expected to drive the market growth during the forecast period. For instance, in February 2018, BeiGene, Ltd. introduced the commercial availability of VIDAZ (azacitidine for injection) in China. VIDAZA is accredited in China for patients with intermediate-2/excessive-chance myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocytic leukaemia. It is marketed in China by BeiGene under an exclusive license from Celgene Corp.

Market Coverage

· The market number available for – 2020-2027

· Base year- 2020

· Forecast period- 2021-2027

· Segment Covered

· Regions Covered- Globally

· Competitive Landscape: Celgene Corp., Otsuka Pharmaceutical Co., Ltd., and Dr. Reddy's Laboratories Ltd., among others.

(Get 15% Discount on Buying this Report)

A full Report of Global Myelodysplastic Syndrome (MDS) Treatment Market is Available at: https://www.omrglobal.com/industry-reports/myelodysplastic-syndrome-mds-treatment-market

Global Myelodysplastic Syndrome (MDS) Treatment Market Report by Segment

By Drug

• Azacitidine

• Lenalidomide

• Decitabine

• Deferasirox

Global Myelodysplastic Syndrome (MDS) Treatment Market by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

Reasons to buy from us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Myelodysplastic Syndrome (MDS) Treatment Share 2021 Growth Challenges, Opportunities and Future Trends 2027 here

News-ID: 2533631 • Views:

More Releases from Orion Market Research

Hair Accessories Market Poised for Strong Growth Driven by Gen Z Trends and Sustainability Preferences
Hair Accessories Market Poised for Strong Growth Driven by Gen Z Trends and Sust …
Hair accessories market was valued at $23.8 billion in 2024 and is projected to reach $55.2 billion in 2035, growing at a CAGR of 8.2% during the forecast period (2025-2035). Generation Z, with significant disposable income, is transforming the hair accessories category in a major way. Their close connection to trends creates a unique feeling of urgency to self-express through fashion, such as clips, scrunchies, and barrettes. It has become
Railway Management System Market Size Analysis, Competitive Insights, Leading Players and Growth Opportunities by 2033
Railway Management System Market Size Analysis, Competitive Insights, Leading Pl …
Railway System (or Railway Management System) market was valued at approximately USD 28.28 billion, and it is expected to reach about USD 45.19 billion by 2033, growing at a CAGR of around 4.8% from 2024 to 2033. Railway Management System Market Overview The Railway Management System market includes technologies and systems used to plan, monitor, and manage railway operations-everything from traffic and signaling systems to asset and maintenance management, passenger information,
Monocalcium Phosphate Market Size Analysis, Competitive Insights, Leading Players and Growth Opportunities by 2033
Monocalcium Phosphate Market Size Analysis, Competitive Insights, Leading Player …
Monocalcium Phosphate market was valued at about USD 4.2 billion, and it is anticipated to reach around USD 6.9 billion by 2033, growing at a CAGR of approximately 5% from 2023 to 2033. Monocalcium Phosphate Market Overview Monocalcium phosphate (MCP) is a calcium-phosphorus compound widely used in animal feed, fertilizers, and also in food and beverage applications (for example as leavening agent or acidity regulator), due to its solubility and bioavailability. The
Automotive Lubricants Market Size Analysis, Competitive Insights, Leading Players and Growth Opportunities by 2033
Automotive Lubricants Market Size Analysis, Competitive Insights, Leading Player …
Automotive Lubricants Market was valued at approximately USD 70.44 billion. By 2033, it is expected to reach around USD 107.09 billion, growing at a CAGR of about 3.3% from 2025 to 2033. Automotive Lubricants Market Overview The automotive lubricants market consists of products like engine oils, gear oils, greases, hydraulic fluids, and transmission fluids that reduce friction, wear and tear, and improve efficiency and lifespan of vehicle components. Demand is driven by

All 5 Releases


More Releases for MDS

Prominent Myelodysplastic Syndrome (MDS) Drugs Market Trend for 2025: Innovative …
What Are the Projected Growth and Market Size Trends for the Myelodysplastic Syndrome (MDS) Drugs Market? The myelodysplastic syndrome (MDS) drugs market has expanded steadily in recent years. It is projected to increase from $3.47 billion in 2024 to $3.73 billion in 2025, reflecting a CAGR of 7.5%. The past growth can be attributed to the aging population, advancements in targeted therapies, ongoing clinical trials, and increased awareness. The myelodysplastic syndrome (MDS)
Myelodysplastic Syndrome (MDS) Treatment Market Insights, Forecast to 2031
"Myelodysplastic Syndrome (MDS) Treatment Market 2024," The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Myelodysplastic Syndrome (MDS) Treatment market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Myelodysplastic Syndrome (MDS) Treatment industry, providing stakeholders
MDS Dental Assisting Academy Brings Flexible Dental Assisting Courses Online
CONTACT: MDS Dental Assisting Academy Address: 122 Thicket Lane City: Freedom State: California Postcode: 95019 Country: USA Telephone: 1-888-637-4732 Website: https://dentalassistanceschool.com/ Email: info@mds4rda.com California, January 28th, 2022: Are you interested in dentistry? What do you think of a career in dental assisting? If being a dental assistant is your career choice, then an RDA program in MDS Dental Assisting Academy will suit you the best. They provide an interactive course
CASwell Secures Products Against MDS Attacks
New firmware updates for network devices & servers against ZombieLoad, RIDL & Fallout Taipei, Taiwan - August 27th, 2019 - CASwell Inc., a leading manufacturer of innovative and high-performance server solutions for SD-WAN (uCPE/vCPE) and network security systems, announced today that most of its network devices and servers have received updates for their firmware or BIOS making them secure against any malicious attacks based on MDS vulnerabilities. With these updates customers
Myeloidysplastic Syndromes (MDS) – Epidemiology Insights (2016-2028)
Myeloidysplastic syndromes (MDS) can be described as a group of hematologic malignancies, that occurr due to abnormality in blood-forming cells in the bone marrow. It is a rare blood cancer and can be mild, moderate or severe, in terms of severity. Download the sample report @ https://www.pharmaproff.com/request-sample/1162 This syndrome can be classified into three main types: MDS with single lineage dysplasia wherein a single type of blood cell appears abnormal; multilineage
Myelodysplastic Syndrome (MDS) Treatment Market Industry Forecast till 2025
Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more